{
    "clinical_study": {
        "@rank": "154979", 
        "brief_summary": {
            "textblock": "Virulizin is an immunotherapy drug preparation that is thought to stimulate the patient's\n      immune system, which in turn may slow the growth of tumors.  It is presented in vials as a\n      sterile preparation for IM injection.  The purpose of the trial is to investigate if\n      Virulizin in combination with gemcitabine provides better efficacy than gemcitabine alone\n      (with placebo) against pancreatic cancer.Virulizin\u00ae efficacy will continue to be assessed if\n      chemotherapy is changed to 5-Fluorouracil."
        }, 
        "brief_title": "A Study to Test the Effectiveness of Virulizin\u00ae Given in Combination With Standard Chemotherapy for Pancreatic Cancer", 
        "condition": "Pancreatic Cancer", 
        "condition_browse": {
            "mesh_term": "Pancreatic Neoplasms"
        }, 
        "detailed_description": {
            "textblock": "A Phase III, Double-blind, Multicenter, Randomized Study in Chemonaive Patients with Locally\n      Advanced or Metastatic Pancreatic Cancer to Compare a Combination Therapy of Virulizin\u00ae plus\n      Gemcitabine versus Placebo plus Gemcitabine; Optional Secondline Therapy may Include\n      Continuation of Virulizin\u00ae or Placebo, Alone or in Combination with 5-Fluorouracil.\n\n      Patients who have not received any prior chemotherapy will be randomized to receive\n      Gemcitabine plus Virulizin\u00ae versus Gemcitabine plus placebo in a double blind fashion. On\n      disease progression patients may be switched to 5-Fluorouracil and continue to receive\n      Virulizin\u00ae or placebo. Patients may continue Virulizin\u00ae alone, if clinically indicated when\n      5-Fluorouracil is discontinued."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "-  Patients with advanced (unresectable or metastatic) pancreatic adenocarcinoma (TNM\n             stages II, III or IV)\n\n          -  No previous systemic chemotherapy(unless given as a radiosensitizer).\n\n          -  ECOG Performance Status 0-2\n\n          -  Life expectancy equal to or greater than 12 weeks\n\n          -  Adequate laboratory and organ functions\n\n          -  Stabilizable pain  (stable analgesic intake)\n\n          -  No radiotherapy during 4 weeks prior to trial entry\n\n          -  No evidence of ascites, pleural effusion or third space fluid accumulation\n\n          -  Not currently using, and have not used in 4 weeks prior to entering trial, systemic\n             steroids or hormonal therapy"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": "400", 
        "firstreceived_date": "June 19, 2002", 
        "id_info": {
            "nct_alias": "NCT00045409", 
            "nct_id": "NCT00040092", 
            "org_study_id": "LOR/VIR/P03/002"
        }, 
        "intervention": {
            "intervention_name": "Virulizin\u00ae", 
            "intervention_type": "Drug"
        }, 
        "keyword": [
            "Virulizin", 
            "Immunotherapy", 
            "Pancreas", 
            "Pancreatic Cancer", 
            "clinical trial"
        ], 
        "lastchanged_date": "January 4, 2008", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "July 2005", 
            "@type": "Actual"
        }, 
        "reference": [
            {
                "PMID": "11139822", 
                "citation": "Ferdinandi ES, Braun DP, Liu C, Zee BC, Ely G. Virulizin(R) - A review of its antineoplastic activity. Expert Opin Investig Drugs. 1999 Oct;8(10):1721-1735."
            }, 
            {
                "PMID": "10762639", 
                "citation": "Liu C, Ferdinandi ES, Ely G, Joshi SS. Virulizin-2gamma, a novel immunotherapeutic agent, in treatment of human pancreatic cancer xenografts. Int J Oncol. 2000 May;16(5):1015-20."
            }, 
            {
                "PMID": "8174313", 
                "citation": "Warner E, Weinroth J, Chang S, MacDonald M, Strauss B. Phase II trial of Virulizin in patients with pancreatic cancer. Clin Invest Med. 1994 Feb;17(1):37-41."
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00040092"
        }, 
        "source": "Lorus Therapeutics", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Lorus Therapeutics", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "July 2002", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2008"
    }, 
    "geocoordinates": {}
}